Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Operating Leases (2019 - 2022)

Rein Therapeutics (RNTX) has disclosed Operating Leases for 4 consecutive years, with $217000.0 as the latest value for Q3 2022.

  • On a quarterly basis, Operating Leases rose 119.19% to $217000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $217000.0, a 119.19% increase, with the full-year FY2021 number at $69000.0, changed N/A from a year prior.
  • Operating Leases was $217000.0 for Q3 2022 at Rein Therapeutics, roughly flat from $217000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $4.9 million in Q1 2019 to a low of $69000.0 in Q4 2021.
  • A 4-year average of $2.4 million and a median of $2.2 million in 2020 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: plummeted 97.64% in 2021, then skyrocketed 119.19% in 2022.
  • Rein Therapeutics' Operating Leases stood at $4.6 million in 2019, then decreased by 8.5% to $4.2 million in 2020, then plummeted by 98.36% to $69000.0 in 2021, then soared by 214.49% to $217000.0 in 2022.
  • Per Business Quant, the three most recent readings for RNTX's Operating Leases are $217000.0 (Q3 2022), $217000.0 (Q2 2022), and $217000.0 (Q1 2022).